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Abstract 
Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which is an effective 
treatment for patients with non‑small cell lung cancer (NSCLC), especially those harboring activating EGFR mutations. 
A previous phase III trial suggested that patients with EGFR wild‑type (EGFR‑wt) NSCLC or elderly patients with disease 
progression after cytotoxic chemotherapy might benefit from erlotinib monotherapy. However, few studies have 
prospectively evaluated the efficacy and safety of second‑ or third‑line erlotinib monotherapy for elderly patients with 
EGFR‑wt advanced or recurrent NSCLC.
Methods: Pretreated patients aged ≥70 years with EGFR‑wt stage IIIB/IV NSCLC or those with postoperative recur‑
rence were enrolled and received oral erlotinib at a dose of 150 mg/day until disease progression. Primary outcome 
was the objective response rate (ORR). Secondary end points included the disease control rate (DCR), progression‑free 
survival (PFS), overall survival (OS), and toxicity profile.
Results: This study was terminated early because of the results from a Japanese phase III trial (DELTA trial). Sixteen 
patients were enrolled between April 2010 and May 2013. The median age was 78 years (range 70–84 years). Six 
patients were female. Five patients had an Eastern Cooperative Oncology Group performance status of 0. Eleven 
(69%) patients had adenocarcinoma. Fifteen (94%) patients were treated with erlotinib as a second‑line therapy. The 
ORR was 0% [95% confidence interval (CI) 0–17.1]. DCR was 56.3% (95% CI 33.2–76.9). The median PFS and OS were 
1.7 months (95% CI 1.3–2.2) and 7.2 months (95% CI 5.6–8.7), respectively. The most commonly occurring adverse 
events included acneiform eruption (31.3%) and skin rash (25.0%). One patient developed grade 3 interstitial lung 
disease, which improved following steroid therapy.
Conclusions: In pretreated elderly patients with advanced or recurrent EGFR‑wt NSCLC, daily oral erlotinib was well 
tolerated; however, administration of the drug should not be considered as a second line therapy.
Trial registration: University Hospital Medical Information Network (UMIN) Clinical Trials Registry UMIN000004561 
(Date of registration: November 15th, 2010)
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Background
In industrialized countries, increasing longevity and 
declining fertility rates are shifting the age distribution 
of populations toward older age groups. Thus, the prev-
alence and incidence of various diseases are increasing, 
and approximately 50% of patients at diagnosis of non-
small cell lung cancer (NSCLC) are >70  years old [1]. 
Studies on various treatments including vinorelbine [2], 
gemcitabine [3], and docetaxel [4] as first-line therapy for 
this population have been conducted. However, the clini-
cal outcomes in terms of tumor response and survival 
were not satisfactory because of the limited efficacy of 
these monotherapies. Prospective studies of second-line 
treatments for this patient population are limited. Thus, 
exploration of an optimal treatment strategy for elderly 
patients with NSCLC, as either first-line or second-line 
therapy is required.
Epidermal growth factor receptor (EGFR) tyrosine 
kinase inhibitor (TKI) treatment, which is less toxic than 
cytotoxic chemotherapy, is the standard treatment option 
for pretreated patients with advanced NSCLC [5, 6]. In 
addition, first-line gefitinib, an EGFR-TKI, is an effec-
tive and feasible treatment for elderly advanced NSCLC 
patients with activating mutations who were relatively 
ineligible for standard chemotherapy [7].
BR.21 was a randomized phase III trial comparing 
EGFR-TKI erlotinib with the best supportive care for 
pretreated patients with advanced NSCLC. The post hoc 
subgroup analysis of the trial showed that elderly and 
EGFR status unknown patients who underwent treat-
ment with erlotinib acquired substantial survival ben-
efit and improved quality of life [8]. Further subgroup 
analysis showed that the patients with EGFR wild-type 
(EGFR-wt) may also benefit from erlotinib [9]. How-
ever, prospective investigation of the clinical benefit of 
erlotinib for pretreated elderly patients with EGFR-wt 
advanced or recurrent NSCLC has not been reported.
We conducted a prospective phase II trial to evalu-
ate the efficacy and tolerability of erlotinib in pretreated 




Eligibility criteria included: age ≥70  years; pathologi-
cally or cytologically proven NSCLC; measurable tumor 
sites according to the Response Evaluation Criteria in 
Solid Tumors (RECIST) guideline version 1.1; an East-
ern Cooperative Oncology Group performance status of 
0–2; no activating EGFR gene mutations (exon 18, 19, 
20 and 21); history of 1–2 regimens of systemic chemo-
therapy; stage IIIB or IV NSCLC, or postoperative recur-
rence; EGFR-TKI treatment naïve; and appropriate organ 
function. Required laboratory criteria were white blood 
cell count >3,000/mm3, neutrophil count >1,500/mm3, 
platelet count >100,000/mm3, hemoglobin >9.0  g/dL, 
aspartate aminotransferase (AST) or alanine aminotrans-
ferase (ALT) <1.5-fold the upper limit of normal (ULN), 
total bilirubin <1.5  mg/dL, and serum creatinine <1.5-
fold the ULN.
Patients who had received chemotherapy within 
4  weeks of trial registration, those who had undergone 
chest radiotherapy within 12  weeks of trial registra-
tion, and those with interstitial lung disease (ILD) were 
excluded.
Baseline pretreatment evaluations included a physical 
examination, chest and abdominal computed tomog-
raphy (CT), brain magnetic resonance imaging (MRI), 
and radionuclide bone scintigraphy or positron emission 
tomography. All images were taken within 4  weeks of 
trial registration.
All enrolled patients provided written informed con-
sent. This study was performed in accordance with the 
Helsinki Declaration of the World Medical Associa-
tion, and the protocol was approved by the Institutional 
Review Board of each participating institution. The main 
Institutional Review Board that approved our trial was 
that of Fukushima Medical University, with an approval 
number of 917 on February 26th, 2009. This study was 
subsequently registered with the University Hospital 
Medical Information Network (UMIN) Clinical Trials 
Registry; identification number, UMIN 000004561.
Assessment of tumor EGFR gene mutation status
EGFR gene mutation analysis was performed using inva-
sive signal amplification reaction using a structure-spe-
cific 5′ nuclease with a polymerase chain reaction (PCR) 
product (PCR-invader) [10].
Assessment of antitumor activity, survival measures, 
and toxicity
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 was used to evaluate tumor response. CT to 
assess target or non-target lesions was conducted every 
4  weeks (MRI for brain, where appropriate, was also 
conducted). A complete response (CR) was defined as 
the disappearance of all target and non-target lesions. 
A partial response (PR) was defined as at least a 30% 
decrease in the sum of the diameters of the target lesions 
compared with the baseline sum of the longest diam-
eters, with no progression of non-target lesions and no 
new lesions [11]. Stable disease (SD) was defined as no 
disease progression or tumor growth for at least 6 weeks. 
Progressive disease (PD) was defined as a 20% increase 
of the sum of measurable lesions, unequivocal progres-
sion of non-measurable lesions, or the appearance of 
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new disease despite treatment. Objective response rate 
(ORR) was defined as the proportion of patients whose 
best response was either CR or PR in the intent-to-treat 
(ITT) analysis. Disease control rate (DCR) was defined 
as the proportion of the patients whose best response 
was CR, PR or SD in the ITT analysis. Progression-free 
survival (PFS) was defined as the time from registration 
to objective tumor progression or death from any cause, 
and overall survival (OS) was the time from registration 
until death. Responses were confirmed by the central 
review board. All toxicities were graded according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (version 3.0).
Treatment regimen
Erlotinib was administrated orally at a dose of 150  mg/
day, and was discontinued if patients developed ≥grade 
2 toxicities. For skin disorders, patients who recovered 
from grade 2 toxicities could restart erlotinib on the same 
dose, whereas in those who improved from grade 3 to 
grade 1 skin disorders, the dose was reduced to 100 mg/
day. Erlotinib treatment was discontinued in cases where 
the following conditions occurred: (1) disease progres-
sion; (2) withdrawal of informed consent; (3) develop-
ment of grade 4 non-hematologic toxicity; and (4) any 
ILD grade. Local therapies such as thoracic surgery/radi-
otherapy and other systemic anti-cancer treatments were 
not permitted during the trial.
Statistical analyses
To determine the number of patients required to power 
the study, we assumed the lower limit of ORR to be 10.0% 
based on the ORR of erlotinib for elderly patients with 
unknown or wild-type status of EGFR mutation, which 
was reported previously as 7.0–10.0% [8, 9, 12, 13], and 
that an ORR of 25.0% in eligible patients would indicate 
potential usefulness. With an alpha value of 0.05 and 80% 
power, we estimated that a total of 40 patients would be 
needed.
The PFS and OS were estimated using the Kaplan–
Meier method. The 95% confidence interval (CI) of the 
response rates were evaluated using the Clopper–Pear-
son method. The statistical analyses were performed 
using SPSS software, version 20 (IBM Corporation, 




This trial was terminated when the results of the DELTA 
trial were presented at the American Society of Clinical 
Oncology (ASCO) Annual Meeting in 2013 [14]. Between 
April 2010 and May 2013, 16 patients were enrolled. 
CONSORT diagram is shown in Figure  1 (Additional 
file 1). All patients assessed for eligibility were assigned 
to receive erlotinib and analyzed. The patients’ baseline 
characteristics are listed in Table 1. The median age was 
78 years (range 70–84), six patients were female, and five 
Assessed for eligibility (n=16)
Excluded (n=0)







Table 1 Patient characteristics
ECOG PS Eastern Cooperative Oncology Group performance status, TNM tumor-
node-metastasis, NOS not otherwise specified.
Patients
n %
Age, years [median (range)] 78 (70–84)
Sex
 Female 6 37.5
 Male 10 62.5
ECOG PS
 0 5 31.3
 1 5 31.3
 2 6 37.4
Histology
 Adenocarcinoma 11 68.8
 Squamous cell carcinoma 2 12.5
 Adenosquamous cell carcinoma 1 6.2
 NOS 2 12.5
Clinical stage (TNM ver.7)
 IIIB 4 25.0
 IV 11 68.8
 Post operative recurrence 1 6.2
No. of prior chemotherapy regimen
 1 15 93.8
 2 1 6.2
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patients had a performance status of 0. Eleven patients 
had adenocarcinoma, two patients had squamous cell 
carcinoma and one patient had adenosquamous carci-
noma. Fifteen (94%) patients were treated with erlotinib 
as a second-line therapy.
Efficacy
All 16 patients were evaluable for response. The ORR 
and DCR were 0.0% (95% CI 0.0–17.1%) and 56.3% (95% 
CI 33.2–76.9%), respectively (Table  2). With a median 
follow-up time of 7.4  months (range 1.3–32.0  months), 
15 (94%) patients experienced disease progression or 
died. Median PFS and OS were 1.7 months (95% CI 1.3–
2.2  months) and 7.2  months (95% CI 5.6–8.7  months), 
respectively (Figure 2).
Safety
The incidence of treatment-related adverse events is 
summarized in Table 3. The most common adverse event 
was grade 1/2 acneiform eruption (31.3%, n = 5 patients), 
followed by skin rash (25.0%, n = 4 patients). All patients 
with adverse skin reactions continued erlotinib, except 
for those with grade 2 toxicity that required temporary 
discontinuation according to the protocol. Grade 3/4 
Table 2 Objective response (RECIST version 1.1)
RECIST response evaluation criteria in solid tumors, CR complete response, PR 
partial response, SD stable disease, PD progressive disease.
n %
Number of patients evaluated 16
 CR 0 0
 PR 0 0
 SD 9 56.3
 PD 7 43.7
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Figure 2 Survival outcomes after erlotinib treatment. Kaplan–Meier estimates of progression‑free survival (a) and overall survival (b). Dot censored 
case at the data cut‑off point.
Table 3 Adverse events (CTCAE version 3.0)
CTCAE Common Terminology Criteria for Adverse Event, AST aspartate ami-
notransferase, ALT alanine aminotransferase.
Adverse event Grade ½, n (%) Grade 3, n (%) Grade 4, n (%)
Anemia 1 (6.3) 0 (0) 0 (0)
Elevation of AST 2 (12.5) 1 (6.3) 0 (0)
Elevation of ALT 2 (12.5) 1 (6.3) 0 (0)
Elevation of creati‑
nine
1 (6.3) 0 (0) 0 (0)
Albuminuria 1 (6.3) 0 (0) 0 (0)
Interstitial lung 
disease
0 (0) 1 (6.3) 0 (0)
Acneiform eruption 5 (31.3) 0 (0) 0 (0)
Rash 4 (25.0) 0 (0) 0 (0)
Dry skin 1 (6.3) 0 (0) 0 (0)
Paronychia 1 (6.3) 0 (0) 0 (0)
Stomatitis 3 (18.8) 0 (0) 0 (0)
Glossitis 1 (6.3) 0 (0) 0 (0)
Diarrhea 2 (12.5) 0 (0) 0 (0)
Anorexia 2 (12.5) 0 (0) 0 (0)
Malaise 1 (6.3) 0 (0) 0 (0)
Hypotension 1 (6.3) 0 (0) 0 (0)
Dysgeusia 1 (6.3) 0 (0) 0 (0)
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non-hematologic toxicities occurred in two patients, one 
with elevated AST and ALT levels (6.3%), and one who 
developed ILD (6.3%). The patient with ILD received sys-
temic steroid therapy and showed full recovery, although 
erlotinib treatment was discontinued. The patient with 
elevated AST/ALT levels, recovered on erlotinib discon-
tinuation, and did not recommence treatment.
Discussion
To the best of our knowledge, this is the first prospec-
tive trial to evaluate erlotinib monotherapy for pretreated 
elderly patients with EGFR-wt NSCLC, although the 
study was terminated early. In this trial, the ORR was 
lower than expected.
Previous clinical trials reported the effectiveness 
of erlotinib for patients with EGFR-wt NSCLC. Sub-
group analysis of BR.21 demonstrated that 7% of non-
squamous EGFR-wt NSCLC patients responded to 
erlotinib and 8% of elderly, EGFR status- unknown 
NSCLC patients responded to erlotinib [8, 9]. The 
SATURN trial investigated the efficacy of erlotinib as 
a switch maintenance therapy following four cycles 
of platinum-based chemotherapy. Compared with the 
placebo in the trial, erlotinib prolonged the survival of 
patients with EGFR-wt NSCLC [12.4 vs 8.7  months, 
HR 0.65 (95% CI 0.48–0.87); p  =  0.0041] [15, 16]. In 
a sharp contrast, several other prospective studies [17, 
18] demonstrated that the ORR of erlotinib monother-
apy in a second-line setting was <5%. In the present 
study, we believe there are several reasons for the low 
ORR. First, the study evaluated elderly patients, who 
most likely have potentially poorer organ function and 
a lower performance status compared with younger 
patients. Second, EGFR status was determined in this 
study by PCR-invader assay, whereas direct sequenc-
ing was used in the BR.21 trial. The sensitivity and 
specificity of direct sequencing has recently been con-
firmed as being lower than those of PCR-based meth-
ods [19–21]. The high specificity of the PCR-invader 
assay may be associated with a more accurate assess-
ment of negative EGFR mutation status, resulting in a 
lower ORR in the current study.
The slow accrual of this study was because of the 
release of data from the TAILOR trial [22]. In addition, 
the study was finally terminated following the disclosure 
of data from the DELTA trial [14], which recruited Japa-
nese NSCLC patients following the TAILOR trial. In both 
studies, erlotinib failed to show any improvement in PFS 
compared with docetaxel in pretreated advanced EGFR-
wt NSCLC patients aged ≥20 years. A recent meta-anal-
ysis also demonstrated that in patients with advanced 
EGFR-wt NSCLC, conventional chemotherapy was 
associated with better improvement of PFS compared 
with first-generation EGFR-TKIs such as gefitinib and 
erlotinib [23]. Therefore, we believe early termination of 
this study was appropriate.
The frequency of skin-related adverse events in the 
current study was comparable to the frequency of skin 
disorders reported in a large-scale erlotinib-treated Japa-
nese cohort [24]. In the current study, all adverse events 
improved with short-term discontinuation, and all but 
two patients with grade 3/4 events recommenced erlo-
tinib treatment. The large-scale Japanese study reported 
that the incidence of ILD was 4.5%, and ILD-related 
death occurred in 1.6% of patients. The higher incidence 
of ILD in the current study was most likely because of the 
small patient population. However, there were no cases of 
ILD-related death.
Conclusions
Erlotinib monotherapy was well tolerated in pretreated 
elderly patients with EGFR-wt advanced or recurrent 
NSCLC. However, erlotinib should not be considered 
as a second line therapy for pretreated EGFR-wt elderly 
NSCLC patients.
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